Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are predicting strong growth driven by the robust sales of Lilly's blockbuster medications, particularly its insulin portfolio. However, there are also concerns about potential challenges